NCT04834674View on ClinicalTrials.gov

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2026

Conditions
Intrahepatic CholangiocarcinomaTransarterial ChemoembolizationApatinibPD-1 Antibody
Interventions
COMBINATION_PRODUCT

DEB-TACE combined with apatinib and PD-1 antibody

combination of local therapy (DEB-TACE), antiangiogenic therapy (apatinib), and immunotherapy (PD-1 antibody)

Trial Locations (1)

610041

RECRUITING

Sichuan Cancer Hospital and Research Institute, Chengdu

All Listed Sponsors
lead

Sichuan Cancer Hospital and Research Institute

OTHER